AIM ImmunoTech Completes DURIPANC Phase 2 Enrollment, Eyes Phase 3 and Collaborations
AIM•AIM ImmunoTech completed patient enrollment and dosing in its DURIPANC Phase 2 trial evaluating Ampligen® with durvalumab for pancreatic cancer, reporting encouraging interim observations and favorable safety. The company highlights ongoing Phase 3 planning, strategic collaborations with AstraZeneca and Erasmus Medical Center, and an expanded intellectual property portfolio.
1. CEO Corner Segment Released
AIM ImmunoTech released a CEO Corner video featuring Thomas Equels discussing Ampligen® progress in pancreatic cancer and outlining upcoming clinical and strategic milestones.
2. DURIPANC Phase 2 Enrollment Completed
The company confirmed full patient enrollment and dosing in its DURIPANC study combining Ampligen® (rintatolimod) with durvalumab, noting encouraging interim clinical observations and continued favorable safety findings.
3. Collaboration and IP Expansion
AIM detailed its strategic collaboration with AstraZeneca on Imfinzi® combinations and with Erasmus Medical Center, alongside the expansion of its Ampligen® intellectual property portfolio.
4. Next-Stage Development Plans
Management highlighted ongoing Phase 3 trial planning, anticipated pivotal-stage catalysts, and the broader potential of Ampligen® to overcome resistance in immunologically cold tumors.
